Get started
NOVAVAX INCNOVAVAX INCNOVAVAX INC

NOVAVAX INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

NVV1 trade ideas

Novavax Technical and Fundamental AnalysisTechnical Analysis - Check/wait if one of the supports will not be broken before buying On a daily chart there might be a Bottom Saucer or Rounding Reversal Pattern Fundamental News: Novavax (NASDAQ:NVAX) is a clinical-stage biotechnology company focused on the discovery, development and commercialisation of vaccines and adjuvants. Through its recombinant nanoparticle vaccine technology, it produces vaccine candidates to respond to both known and newly emerging diseases. Novavax topped Wall Street expectations for the first quarter when it reported a loss of 58 cents per share on revenue of $3.4 million earlier this month. Analysts were expecting a loss of 69 cents per share and revenue of $1.9 million. More importantly, the biotech company announced in its earnings release that the Oslo-based nonprofit Coalition for Epidemic Preparedness Innovations will invest $384 million to advance the clinical development of its SARS-CoV-2 vaccine candidate, NVX-CoV2373. Novavax plans to start human trials in May with preliminary results expected in July.
NASDAQ:NVAX
by Mauriello
[NVAX] Sliding Back to $40, Collapse if It Breaks ThroughI missed this guy when I jumped on MRNA and INO earlier this week. Just trying to pin this one down a bit, coronavirus stocks are wild and fun :). For FOMO stocks, typical support and resistance horizontal lines aren't as predictive and you should instead look to the Volume Profile. Support should be right around the POC, which is $40. It should slide down to that and hang a bit before breaking through and crashing down. May bounce back up too but seems unlikely. All indicators are lining up at the start of a downward channel and signaling a short move too. June market crash is probably gonna move this more than anything as retail tries to secure their tiny profits or stem their massive losses.
NASDAQ:NVAXShort
by ProfitHarvest
8
$NVAX can rise in the next daysContextual immersion trading strategy idea. Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The share price rose after good earnings. I see some preconditions the share price will continue growing. The demand for shares of the company still looks higher than the supply. These and other conditions can cause a rise in the share price in the next days. So I opened a long position from $43,15; stop-loss — $42,26. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:NVAXLong
by KozakHlib
Novavax (NVAX): Tell me about my Schiff!I'm bull-ish on Novavax (see Related Idea). I think their approach to the COVID-19 vaccine is promising - their recombinant nanoparticle vaccine technology and Matrix-M adjuvant. They also have positive long-term prospects with their proprietary NanoFlu candidate. This is the big one to me. It's unclear whether COVID-19 becomes seasonal or not but influenza is established and recurring. It fact, it's becoming more difficult to handle with every year. The strains are becoming more advanced and unpredictable. Whether or not Novavax can produce a profitable candidate, I simply don't know. I believe that their patented tech is promising. Novavax might not produce a COVID vaccine before its competitors (or at all) but they continue to demonstrate their technology and approach works. Example: ir.novavax.com That being said, tell me about this random Schiff I plotted :) Matrix-M Adjuvant: novavax.com NanoFlu Phase 3 topline data: novavax.com RSV F Vaccine: novavax.com
NASDAQ:NVAXLong
by traderman001
4
Novavax Big Break Out Day!- $NVAX, +30.80% as it rallied after the biotech announced it received a large $384m investment for its COVID-19 vaccine candidate and beat Earnings expectations. - Technically we are in a strong uptrend - just broken out of its corrective move down. This is the type of stock which may take off further quite quickly - we could wait for a pullback (possibly at the old highs) or buy this breakout at the open market. Will depend on your risk appetite. - Targets have been set based on the Pitchforks and Median Line Theory.
NASDAQ:NVAXLong
by Tuhi_Capital
2
NVAX - Setting up nicely for ShortWith 100% implied volatility - and 3 month options costing 225% of Implied Vol. You can safely bet on a short, soon you pick the top with your fav strategy. Analysis - This whole run up is for a huge offering. Company has no cash or cash equivalent. Upcoming obligations - $342k + unknown research cost and operating expenses. If I read this correctly, About 4.9M shares are going to be dumped (Around $30 peak, or before) Soon will roll down. - Looking for 3 month mark. secfilings.nasdaq.com secfilings.nasdaq.com
NASDAQ:NVAXEducation
by UDAY_C_Santhakumar
5
$NVAX Play The Break Out Above $18$NVAX is setting up as nice day trade if we get above $18 and the 52 week high of $18.25 a share. We could see $20 a share pretty easy, especially with the news out today. MELBOURNE, Australia, April 16, 2020 /PRNewswire/ -- As part of the urgent global race to develop a vaccine to tackle the Coronavirus COVID-19 outbreak, Nucleus is due to commence Phase 1 testing for the Novavax SARS-CoV-2 Recombinant Spike Protein Nanoparticle vaccine, NVX-CoV2373, at its Melbourne and Brisbane clinics within the coming weeks. "Nucleus has a rich history of Phase 1 vaccine trials, and a long-standing track-record with Novavax (NVAX)," says Nucleus CEO Cameron Johnson. "This is the third confirmed global COVID19 vaccine trial and the first in Australia and we are well positioned to implement rapid testing with first-in-human trials over the coming weeks. "With the capacity to conduct this trial across both our Melbourne and Brisbane clinics, we will be assisting Novavax to undertake Phase 1 trials and fast track NVX-CoV2373 to potential subsequent development as soon as possible," adds Johnson. Novavax's early development efforts on vaccines for two other recent coronavirus epidemics – severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), along with prior work on Ebola (phase 1 trial conducted in Australia) – allows them to leverage their understanding of coronaviruses and adapt their research to create a vaccine for SARS-CoV-2, the virus that causes COVID-19. "The urgent global race to develop a vaccine against the COVID-19 pandemic drove our rapid identification and selection of an optimal, highly immunogenic vaccine candidate," said Stanley C. Erck, President and CEO of Novavax. "We are pleased that Nucleus, our long-time partner, was able to accommodate our accelerated timeline." The Phase 1 trial of NVX-CoV2373 is expected to begin in mid-May with preliminary immunogenicity and safety results in July. The scale and absolute commitment to the highest standards make Nucleus the ideal partner in the rapid development of the vaccine for COVID-19. "We own 150 of the total 250 dedicated phase I beds available in Australia over two sites in Melbourne and Brisbane, located within major medical precincts. Supported by our workforce of over 400 specialists, we are in the unique position of offering sponsors a multi-site pathway to conduct their clinical trials," says Johnson. This scale allows Nucleus to address the urgency of the COVID-19 vaccine studies, without interruption to other ongoing clinical trials. The standards ensure the reliability of the studies, especially in the current pandemic situation across the world. "For all of our clinical trials, Nucleus has implemented the highest level of Transmission-Based Precautions within its clinical units including the creation of dedicated teams of clinical staff," says Nucleus Infectious Diseases Physician and Microbiologist and, Associate Professor of Medicine at the University of Queensland, Dr Paul Griffin. "These staff are assigned to work only in functional designated areas and there is no cross-pollination of these teams, improving safety, reducing study risk, and ensuring integrity of the trials." As a key partner in the development of these promising vaccine candidates, Nucleus' role in solving the current pandemic is top of mind for Johnson. "As COVID-19 continues to impact the everyday life of all global citizens, finding a solution has become an urgent objective for governments and health organisations around the world. The world is watching and we're on the front line, supporting Novavax to unlock the potential of a Coronavirus COVID-19 vaccine." Good luck to all!
NASDAQ:NVAXLong
by InsiderFinancial
6
It's hard to overstate how important the NVAX Phase 3 result isNovavax's Nanoflu isn't your typical new drug-- it's a whole new pharmaceutical technology. So it's hard to overstate how important today's positive Phase 3 clinical trial result is. Positive Phase 3 trial data this morning suggest that Novavax's Virus-Like Particle (VLP)-based flu vaccines will be much more effective than existing egg-based vaccines. When you make a vaccine in an egg, it can mutate in the egg and no longer match the flu strains it's supposed to prevent. The VLP vaccines, by contrast, are genetically identical to the targeted flu strains. This increases the vaccines' effectiveness against the targeted strains. Nanoflu also includes something called "adjuvant Matrix-M," which increases the number of antibodies produced in response to the vaccine by something on the order of 50%. Stronger immune response means greater effectiveness, though it also modestly increased the incidence of adverse events in Novavax's trial. One particular important result from the Phase 3 trial was that Nanoflu was more effective than its competitors against A/H3N2, the most lethal family of flu viruses and the one against which vaccines have traditionally been least effective. I have some friends doing work in this field, and they've told me that there are three really exciting things about these VLP vaccines: 1) they aren't infectious, which makes them safer than using an attenuated virus, 2) they protect against not only the strain of virus they target, but also some mutant forms of it, and 3) they take 12 weeks to produce rather than the traditional 9 months. This last point is the real game-changer. Imagine being able to get vaccines to market in a third of the traditional time. Novavax is also working on a VLP-based Covid-19 vaccine. We can probably expect the FDA to rush approval of both Nanoflu and the CoV-19 vaccine.
NASDAQ:NVAXLong
by ChristopherCarrollSmith
5